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Highlights 
 People who inject drugs experienced discrimination frequently. 
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 Frequent discrimination was linked with poorer health and wellbeing in our sample. 
 Discriminated females and Indigenous people had the poorest health and wellbeing. 
 
Abstract 
Background: Previous research has shown that people who inject drugs (PWID) experience 
discrimination on a regular basis. This study explores the relationships between 
discrimination against PWID and health and wellbeing. 
Methods: Data on discrimination against PWID and their health and wellbeing were drawn 
from the Illicit Drug Reporting System collected in Australia in 2016. The Personal 
Wellbeing Index was used to measure wellbeing, and the Kessler-10 scale was used to 
measure psychological distress. Experience of overdose, injecting related illnesses, diseases, 
and risky injecting behaviour were also assessed. We fitted multivariate logistic regression 
models adjusted for socio-demographic, imprisonment history, and drug-related factors. 
Results: Of the 796 participants included in the study, the majority who reported 
experiencing discrimination were male (65%), heterosexual (89%), and unemployed (89%). 
Thirty percent of the sample (n=238) reported they had never experienced discrimination 
because of their injecting drug use. Seventeen percent of participants had not experienced 
discrimination in the twelve months prior to the interview, 24% experienced discrimination 
monthly, 16% experienced discrimination weekly, and 13% experienced discrimination daily 
or more. Frequent discrimination was associated with increased odds of overdosing, injecting 
related illnesses and diseases, mental health issues, and poor wellbeing. Among those who 
reported experiencing discrimination, females and those who identified as Indigenous were 
found to have poorer health and wellbeing outcomes. 
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Conclusions: Our findings highlighted that frequent discrimination may lead to worse health 
and wellbeing among PWID. If our findings are supported by other research, policies aimed 
at reducing discrimination against PWID may be warranted or improved. 
 
Keywords: People Who Inject Drugs; Injecting Drug Use; Discrimination; Stigma; Health; 
Wellbeing 
 
1. Background 
 Injecting drug use is the most stigmatised among all routes of illicit drug 
administration (Ahern et al., 2007), as it is seen as the ultimate breach of social conventions 
in contemporary society (Treloar et al., 2013; Manderson, 1995). Stigma, as a sign of low 
moral status (Goffman, 1986), is followed by discrimination (Sartorius, 2006), which is 
defined as actions from a dominant group or group member that aim to harm other 
individuals that are part of less dominant groups (Huddy et al., 2013). Discrimination may 
generate adverse social and individual outcomes in those discriminated against. Experiencing 
discrimination is especially damaging for PWID, as it is shown to happen in diverse settings 
including employment, health, and welfare and is perpetrated by a variety of social actors 
such as employers and co-workers (Earnshaw et al., 2013), health providers (Sarin and 
Kerrigan, 2012; Simmonds and Coomber, 2009), and members of the general public 
(Davidson et al., 2012; Gayen et al., 2012; McKenna, 2013). As such, discrimination can be a 
catalyst for ongoing denials and exclusions for PWID.  
 These settings are mainly places that PWID seek out in order to improve their health, 
wellbeing, and life standards. Work, for example, is important in the lives of mainstream 
society members, and evidence shows that holding a job is beneficial not only in its financial 
aspect but also for individuals’ physical and mental health and general wellbeing (Waddell 
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and Burton, 2006). PWID are largely unemployed and are shown to have difficulty finding 
and/or securing a job for a range of reasons, one of which includes discrimination attached to 
their injecting drug use (Sarin and Kerrigan, 2012).  
 Discrimination may also be a barrier for those who choose to change their injecting 
drug behaviour by engaging in opioid substitution treatment (OST). Beginning OST presents 
a number of difficulties. In addition to the immediate challenges of coping with withdrawal 
symptoms, social ties to PWID who are not in treatment, and temptation to use other drugs, 
there is evidence of discrimination against PWID in OST dispensing pharmacies. Pharmacy 
staff have been shown to prioritise other customers over PWID on OST, resulting in long 
waiting times (Davidson et al., 2012; Simmonds and Coomber, 2009).  
 Similarly, welfare settings can be a source of discrimination. The 2016 Australian 
Illicit Drug Reporting System (IDRS) report suggested that PWID experienced discrimination 
regularly when attempting to access welfare services (Stafford and Breen, 2017), most 
notably when they try to secure and/or maintain safe accommodation. Considering that 80% 
of participants in this sample reported being homeless, it is important to determine whether 
discrimination from the welfare system perpetrates a lifestyle of homelessness (Stafford and 
Breen, 2017). Further, PWID have also reported being discriminated against in public places, 
which can happen more frequently when people are homeless (Stafford and Breen, 2017). A 
lack of safe accommodation is also associated with poor overall health and wellbeing, and 
previous studies have identified relationships between discrimination and adverse physical 
and mental health outcomes among PWID (Sarin and Kerrigan, 2012; Neale et al., 2008; 
Davidson et al., 2012; Wilson et al., 2014; Gayen et al., 2012).  
 Previous studies have found links between stigma, discrimination, and the health and 
wellbeing of people who use drugs (Cama et al., 2016; van Boekel et al., 2013) and have 
highlighted the importance of reducing discrimination in health and social care contexts 
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(Brener et al., 2010; Neale et al., 2008). However, beyond this initial evidence, there is 
limited understanding of whether frequency of discrimination impacts the health, wellbeing, 
and welfare of PWID. Investigating the relationship between frequent discrimination and the 
health and wellbeing of the PWID can expand the literature on this topic and give new insight 
into aspects of discrimination that are more pronounced for PWID (Bullen, 2010; Rivera et 
al., 2014). This paper will explore whether frequency of discrimination impacts on the health 
and wellbeing of a national sample of PWID in Australia. 
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 2. Methodology 
 2.1 Study design  
 Each year, a sentinel sample of approximately 800 people who regularly inject illicit 
drugs is recruited across all State and Territory capitals in Australia for the Illicit Drug 
Reporting System (IDRS) survey. Participants are recruited using social media 
advertisements, posters in relevant health facilities, and word of mouth. The questionnaire 
asks about their patterns of drug use, involvement in crime, use of health services, and their 
health and wellbeing. Interviews last approximately one hour and are conducted in Needle 
and Syringe Program facilities by trained non-judgmental interviewers. The IDRS 
methodology is extensively described elsewhere (Hando et al., 1998). Ethics approval was 
obtained from local ethics committees from each State and Territory as well as from the 
University of New South Wales Human Research Ethics Committee. Participants provided 
informed consent and upon completion of interview were reimbursed forty Australian dollars. 
Participants were eligible if they were seventeen years or older, injected drugs regularly (i.e., 
at least monthly) in the six months prior to interview, and had lived in the city of interview 
for at least twelve months prior to the interview. Participants who have been away from the 
local market for more than 2 months, e.g., due to incarceration or residential treatment, are 
ineligible for the IDRS. 
 2.2 Measures 
 Participants were asked how often, on average, they had been treated differently to 
other people and believed it was because they were PWID (never /not in the previous twelve 
months, monthly, weekly+).  
 We recoded experience of overdose and injecting related illnesses and diseases (dirty 
hit 1, abscesses or infections from injecting, difficulty injecting, and thrombosis or blood 
                                                          
1 An injection that makes the person feel sick. 
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clots) in the month prior to interview. We also recorded engagement in unsafe injecting 
behaviour using two items inquiring about borrowing needles and/or injecting equipment in 
the previous month (no/yes). We asked participants to report any mental health issues in the 
six months prior to the interview (no/yes) and assessed psychological distress by 
dichotomising the 50 scores from the Kessler-10 scale [“low or no distress” (score 0–15) and 
“moderate/high/very high distress” (score 16–50)] (Kessler et al., 2002).  
 We asked participants to rate their general health between excellent/good (0) and 
fair/poor (1). We also used the validated scale Personal Wellbeing Index (PWI) (International 
Wellbeing Group, 2013) to compare our sample mean with the Australian population mean. 
The seven items of the PWI were summed to generate a total score ranging from 0–63. We 
converted the score reported in the 2016 Australian Unity Wellbeing Index survey (76.7 out 
of a possible 100) (The Australian Unity Wellbeing Research Team, 2016) using the formula 
from the PWI manual (Supplementary Figure2). This yielded a corresponding Australian 
mean score of 49, which we used to generate a binary variable indicating scores equal to or 
above (0) or below the Australian mean (1). We also used current or recent experience of 
homelessness as another indicator of wellbeing (Steiner et al., 1995), which was coded as 
past (0) and current/recent homelessness (1). 
 2.3 Data analysis and covariates 
 We used descriptive analyses to investigate differences in health and wellbeing by 
frequency of discrimination and cross-tabulated with potential confounders. We then used 
multivariate logistic regression analysis to model relationships between frequency of 
experience of discrimination and indicators of health and wellbeing using the standard p-
value (p<.05).  
                                                          
2 Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by 
entering doi: ... 
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 Covariates which were associated with either the dependent or independent variables 
were included in the analyses. These were age, gender, employment status, Aboriginal/Torres 
Strait Islander status, education level, accommodation type, most injected drug, age of first 
injection, frequency of injecting, if currently in treatment, prison history, and if arrested in the 
previous twelve months. We conducted interaction analyses where covariates appeared to 
reduce the association between discrimination and our outcomes of interest. Missing data 
represented 7.5% of the total sample of people who reported discrimination, and there were 
no differences between those lost to follow up and those who remained in the study (results 
not shown).  
 3. Results 
 From a total of 796 respondents, 29.9% reported they had never been treated 
differently to other people because of their injecting drug use, 17.1% had not experienced 
discrimination in the twelve months prior to the interview, 24.4% experienced discrimination 
monthly, and 28.7% experienced discrimination weekly or more often.  
 Gender and current treatment were associated with experience of discrimination 
(Table 1). In adjusted models, more frequent experiences of discrimination (monthly+) were 
associated with increased likelihood of reporting poorer physical health (including injecting 
related problems), poorer mental health and wellbeing, experience of overdose, abscesses or 
infections from injecting, and poorer general health (Table 2). We further investigated 
differences between those who experienced discrimination monthly and those who 
experienced it weekly or more and found no differences between the two groups 
(Supplementary Table3). In interaction models, the risk of having difficulty injecting was 
over 40% higher for females, and the risk of self-reporting mental health problems was 33% 
higher among those experiencing discrimination weekly or more often (Table 3). The risk of 
                                                          
3 Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by 
entering doi: ... 
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self-reported mental health problems was nearly three times higher for people who identified 
as Aboriginal/Torres Strait Islander than it was for non-Indigenous participants (Table 4). 
 4. Discussion 
 Our results showed that nearly half of the sample reported experiencing 
discrimination in the previous 12 months. When compared to people who reported they had 
not experienced frequent discrimination (within previous twelve months), those who had 
were more likely to report an overdose, injecting related illnesses and diseases, poor mental 
health, and poor wellbeing. Our study showed that frequent experience of discrimination was 
associated with three out of seven injecting-related risks, illnesses, and diseases. Frequent 
experience of discrimination was also associated with one out of two mental health indicators 
and all three wellbeing indicators. This builds upon previous research demonstrating an 
overall link between discrimination and mental and physical health (Couto e Cruz et al., 
Unpublished results; Young et al., 2005; Cama et al., 2016; Treloar et al., 2013). 
 Our findings on frequent discrimination and indicators of poorer health and wellbeing 
are in accordance with other research showing that frequent experience of discrimination 
among a racial minority was linked with poorer psychological adjustment (Huynh et al., 
2012). Our findings are also in line with a meta-analytic review showing that recent life 
events are linked with psychotic disorders/experiences (Beards et al., 2013). Our study 
supports the view that constant negative reinforcements generated by discrimination may 
have a cumulative impact on health and wellbeing. We also highlight the relevance of 
assessing the timeframe of the experience of discrimination in future research and analysing 
its health correlates.  
 There is a paucity of literature that has explored the relationship between 
discrimination against PWID and injecting-related risks and harms. Our findings linking 
discrimination against PWID with overdose and injection-related harms (abscesses or 
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infections from injecting and difficulty injecting) is a significant contribution to this limited 
literature. These findings are partly supported by a recent systematic review linking risky 
injecting behaviour among PWID with discrimination against PWID by Needle and Syringe 
Program staff (Couto e Cruz et al., in press). In light of a successful antidiscrimination 
training implemented among drug and alcohol workers in an Australian state (Brener et al., 
2017), we argue that there is a need to include welfare and other health workers in such 
training and expand it to a national level. 
 Our results also show that the likelihood of injecting-related illnesses and diseases and 
poor mental health are higher among females who experience discrimination. This may be 
explained by recent findings that women experience more mental health problems than men 
(Australian Bureau of Statistics, 2015) and are also more likely to be injected by others, 
increasing the risk of associated harms (Zahidie et al., 2013). However, females who use 
drugs tend to be viewed more harshly than men, often due to public perceptions of them as 
“bad mothers”, and so they may be more affected by discrimination than men (McKenna, 
2013; Earnshaw et al., 2013).  
 We showed that Aboriginal and Torres Strait Islander PWID were less likely to have 
their health and wellbeing affected by injecting related discrimination. However, when 
discrimination was reported as very frequent (weekly or more often), the interaction model 
indicated a higher risk of mental health problems among Indigenous PWID when compared 
to non-Indigenous participants. Taken together, these findings reinforce the need to develop 
anti-discrimination strategies that consider the specificities of gender and Indigenous status. 
 The present study has some limitations. Our data does not differentiate between 
discrimination experienced infrequently over the last year and discrimination experienced 
monthly or more. Also, our study is based on cross-sectional data. There is a need to explore 
these issues in longitudinal studies in order to identify whether causal links can be made 
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between discrimination and poorer health and wellbeing, the directionality of the relationship, 
and whether frequent discrimination is the more influential issue. In order to advance the 
current literature, there is also a need to investigate how the setting of discrimination, indexed 
by the purpose of the venue (e.g., home, health care, public space), is related to health and 
wellbeing for PWID.  
 5. Conclusion 
 The evidence we presented showing links between frequent discrimination and poor 
health and wellbeing in PWID advances understanding of the features of discrimination 
against PWID. It may be used to develop new strategies aimed at reducing discrimination and 
could also be used to improve existing anti-discrimination policies.  
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Table 1. Distributions of socio-demographic covariates by the frequency of discrimination 
 
Frequency of Discrimination 
Variables 
Not in 
the 
previous 
12 
months 
(%) 
Monthly 
(%) 
Weekly 
or 
more 
(%) 
Relationship 
Chi-squared 
value (P-
value) 
Age (n=796) n=374 n=194 n=228 0.255 
Younger than 40 years old 38 43 45 
 40 years old or more 62 57 55 
 Gender (n=795) n=373 n=194 n=228 0.015 
Female  27 32 38 
 Male 74 68 62 
 
Employment Status (n=787) n=368 n=193 n=226 0.045 
Not employed 89 86 94 
 Worker 10 14 5 
 Student 1 1 1 
 Aboriginal/Torres Strait Islander 
(n=795) 
n=373 n=194 n=228 0.479 
No  81 85 82 
 Yes 19 15 18 
 Education Level (n=796) n=374 n=194 n=228 0.244 
Year 11 or 12 31 30 36 
 Year 10 or less 70 70 64 
 Accommodation Type a (n=770) n=363 n=186 n=221 0.001 
Stable accommodation 80 80 67 
 Non-stable accommodation 20 20 33 
 Most injected drug (n=780) n=396 n=188 n=223 0.476 
Heroin 38 39 43 
 OST b/Other opiates 21 21 16 
 Stimulants 40 40 41 
 Age of first injection (n=796) n=374 n=194 n=228 0.649 
14 or less 15 16 21 
 15-18 38 35 38 
 19-25 31 31 26 
 26-35 13 16 12 
 36+ 4 4 3 
 Frequency of injection (n=796) n=374 n=194 n=228 0.299 
Weekly or less 20 16 13 
 More than  weekly, not daily 38 39 39 
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Daily or more 43 45 48 
 If in treatment (n=795) n=373 n=194 n=228 0.021 
Not in treatment 61 59 50 
 In treatment 39 41 50   
a Stable accommodation: Own house/flat or rented house/flat. Non-stable accommodation: 
Parent's/family home, boarding house/hostel, Shelter/refuge, drug treatment residence, no fixed 
address/homeless 
b Medication provided on Opioid Substitution Therapy 
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Table 2. Models of health for PWID in relation to timeframe of discrimination 
  Injecting related risks, illnesses and diseases Mental Health Wellbeing 
  
 Overdose 
Dirt
y 
Hit  
Abscess
es or 
infectio
ns from 
injectin
g c 
Promine
nt 
scarring 
or 
bruising 
c 
Difficul
ty 
Injectin
g c 
Thrombo
sis or  
blood 
clots c 
Injectin
g risky 
behavio
ur c 
Self-
reporte
d 
Mental 
Health 
Proble
ms d  
Mod. 
to 
high 
menta
l 
distre
ss  
(K-
10) c 
Recently 
homeless 
Gener
al 
health 
poor 
or fair 
Wellbei
ng 
Below 
Australi
an mean    
(PWI-A) 
b c 
  AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR 
  CI95 CI95 CI95 CI95 CI95 CI95 CI95 CI95 CI95 CI95 CI95 CI95 
Discriminat
ed monthly 
1.2 0.9 1.9 1.2 1.5 2.5 1.1 1.6 0.8 1.9 1.3 1.7 
  0.8-1.7 
0.4-
1.9 
0.9-4.0 0.8-1.8 1.0-2.2 0.9-6.9 0.5-2.5 1.1-2.3 
0.3-
2.2 
1.2-2.9 0.9-1.9 1.1-2.8 
Discriminat
ed  weekly 
or more 
1.6 1 2.9 1.2 2 2.5 1.5 1.8 1.6 2 2 2.9 
  1.1-2.2 
0.5-
2.1 
1.5-5.7 0.8-1.7 1.4-2.8 1.0-6.5 0.7-3.0 1.2-2.6 
0.4-
6.5 
1.3-3.0 1.4-2.9 1.7-4.8 
≥ 40 years 
old  
1.6 0.8 1 0.8 1.1 1.4 0.3 1.1 0.6 0.7 2.2 1 
  1.1-2.2 
0.4-
1.5 
0.6-1.9 0.6-1.1 0.8-1.6 0.6-3.3 0.2-0.6 0.8-1.5 
0.2-
1.7 
0.4-0.9 1.6-3.1 0.7-1.4 
Male 1 0.4 0.8 0.6 0.5 0.8 0.8 0.7 0.7 1.5 0.8 1 
  0.7-1.4 
0.2-
0.8 
0.4-1.5 0.4-0.9 0.3-0.7 0.3-1.9 0.4-1.6 0.5-1.0 
0.2-
2.4 
1.0-2.3 0.5-1.1 0.6-1.5 
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Aboriginal/ 
Torres Strait 
Island origin 
0.6 0.6 0.7 0.7 0.6 0.4 1.2 0.4 1 1.1 0.8 0.4 
  0.4-0.9 
0.2-
1.4 
0.3-1.5 0.5-1.1 0.4-0.9 0.1-1.5 0.6-2.6 0.3-0.7 
0.3-
3.7 
0.7-1.7 0.5-1.2 0.3-0.7 
Completed 
up to year 10  
at school 
1.4 0.9 0.8 1 0.8 0.7 1 1.1 0.4 0.6 0.7 - 
  1.0-1.9 
0.5-
1.7 
0.4-1.5 0.7-1.4 0.6-1.2 0.3-1.7 0.5-2.0 0.8-1.6 
0.1-
1.5 
0.4-1.0 0.5-0.9 - 
Worker 0.6 1.2 0.7 1 1 0.3 1.2 0.6 0.4 0.5 0.9 - 
  0.3-1.0 
0.4-
3.3 
0.2-2.4 0.6-1.7 0.6-1.8 0.0-2.2 0.4-3.3 0.3-1.1 
0.1-
1.3 
0.2-0.9 0.5-1.6 - 
Student 0.6 1 1 0.7 1.1 1 1 1.4 1 1 0.7 - 
  
0.1-2.7 
1.0-
1.0 
1.0-1.0 0.2-3.0 0.2-4.9 1.0-1.0 1.0-1.0 0.3-5.9 
1.0-
1.0 
1.0-1.0 0.1-4.0 - 
Non-stable 
accommodat
ion 
0.7 0.8 1.5 1 1.1 0.6 1.2 1.1 2.2 - 1 - 
  0.5-1.1 
0.3-
1.7 
0.8-2.8 0.7-1.5 0.7-1.6 0.2-1.8 0.6-2.4 0.8-1.6 
0.5-
10.3 
- 0.7-1.5 - 
In treatment 1.4 1.9 0.9 1.2 1.4 2.1 0.6 1.3 1 0.5 1 0.9 
  1.0-1.9 
1.0-
3.5 
0.5-1.7 0.9-1.7 1.0-1.9 0.9-4.7 0.3-1.1 1.0-1.8 
0.3-
2.7 
0.3-0.7 0.7-1.3 0.6-1.3 
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Age of first 
injection 
between 15-
18 years old 
0.9 0.8 1.3 1.2 1.3 3.2 1.2 0.8 1.3 0.7 0.7 0.7 
 
0.5-1.4 
0.4-
1.9 
0.6-3.2 0.7-1.9 0.8-2.1 0.8-12.0 0.4-3.5 0.5-1.2 
0.3-
5.3 
0.4-1.1 0.4-1.1 0.4-1.3 
Age of first 
injection 
between 19-
25 years old 
0.8 0.6 1 0.7 1.2 1 2.3 0.7 2.1 1.2 0.6 0.8 
 
0.5-1.3 
0.2-
1.4 
0.4-2.5 0.4-1.1 0.7-2.0 0.2-4.8 0.8-6.4 0.4-1.1 
0.4-
10.9 
0.7-2.1 0.4-1.0 0.5-1.6 
Age of first 
injection 
between 26-
35 years old 
0.6 0.5 1.5 1.2 1.3 3.7 3.1 1.3 3.6 0.7 0.8 0.9 
 
0.3-1.0 
0.2-
1.7 
0.5-4.1 0.7-2.1 0.7-2.4 0.8-16.9 1.0-9.4 0.7-2.3 
0.3-
38.4 
0.4-1.3 0.5-1.5 0.4-2.0 
Age of first 
injection ≥  
36 years old 
0.3 1 1.5 0.7 0.9 1 1 1 0.3 0.9 0.7 1.1 
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  0.1-0.9 
1.0-
1.0 
0.3-6.7 0.3-1.8 0.3-2.5 1.0-1.0 1.0-1.0 0.4-2.6 
0.0-
2.7 
0.3-2.7 0.3-1.8 0.3-4.0 
OST/Other 
opiates e 
0.7 2.3 2.1 0.9 1.4 1.9 0.3 0.8 1 0.6 1.6 1.1 
  0.5-1.1 
1.1-
4.9 
1.0-4.4 0.6-1.4 0.9-2.1 0.7-5.0 0.1-0.9 0.5-1.3 
0.2-
4.3 
0.4-1.1 1.1-2.5 0.6-1.8 
Stimulants f 0.7 1.3 1.2 1 1 1 0.5 1.1 0.5 1 0.8 0.9 
  0.5-1.0 
0.6-
2.8 
0.6-2.5 0.7-1.4 0.7-1.5 0.4-2.8 0.2-1.0 0.8-1.6 
0.2-
1.7 
0.7-1.6 0.6-1.2 0.5-1.3 
Inject more 
than weekly, 
but not daily 
1.1 1.8 1.2 1.8 1.6 0.7 1.9 0.9 0.5 1 1.2 1.3 
  0.7-1.8 
0.6-
5.6 
0.5-3.1 1.1-2.8 1.0-2.5 0.2-2.5 0.7-5.3 0.6-1.4 
0.1-
2.0 
0.6-1.7 0.8-1.9 0.8-2.2 
Inject daily 
or more 
1.1 2.9 1.8 2.3 1.8 2.1 1.3 0.7 1 1.4 1.2 1.3 
  0.7-1.8 
0.9-
8.6 
0.7-4.6 1.5-3.7 1.1-2.9 0.6-7.1 0.5-3.7 0.5-1.1 
0.2-
4.7 
0.8-2.3 0.8-2.0 0.8-2.2 
Ever in 
prison 
1.6 1.2 0.9 1 1.1 0.7 1.2 0.7 0.5 1.1 1.1 1.1 
  1.2-2.3 
0.6-
2.3 
0.5-1.7 0.7-1.4 0.8-1.5 0.3-1.6 0.6-2.3 0.5-1.0 
0.2-
1.4 
0.8-1.7 0.8-1.5 0.7-1.6 
Arrested in 
the previous 
12m 
1.2 1 0.7 1 1.1 2 1.4 1.3 1.1 3 1.1 1.5 
  
0.9-1.7 
0.5-
1.9 
0.4-1.3 0.7-1.4 0.8-1.5 0.9-4.7 0.7-2.6 0.9-1.8 
0.4-
3.1 
2.1-4.4 0.8-1.6 1.0-2.3 
Note1: Each column above represents a separate model. 
Note2: The model 'Recently homeless' was not adjusted for 'accommodation type' and the model 'Personal Wellbeing Index' was not adjusted for 'accommodation type', 'employment status' and 
‘education level’. 
a Exceptions noted above, all models were adjusted for age, gender, employment status, Aboriginal or Torres Straight Island origin, education level, accommodation type, most injected drug, 
age of first injection, frequency of injection, if currently in treatment, if arrested in the previous 12 months and if ever in prison. 
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b Lifetime 
c Previous month 
d Previous six months 
e OST/opiates other than heroin as the most injected drug 
f Stimulants as the most injected drugs 
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Table 3. Interaction model of health indicators in relation to timeframe of discrimination, by gender 
 
Any gender Females Males 
Dirty Hit 
   Discriminated monthly 0.9 (0.4-1.9) 0.3 (0.1-1.4) 1.6 (0.6-4.6) 
Discriminated  weekly or 
more 
1.0 (0.5-2.1) 0.4 (0.1-1.2) 2.2 (0.8-6.0) 
Prominent Scarring or 
bruising 
   Discriminated monthly 1.2 (0.8-1.8) 2.6 (1.2-5.6) 0.9 (0.6-1.4) 
Discriminated  weekly or 
more 1.2 (0.8-1.7) 1.6 (0.8-3.2) 1.0 (0.6-1.6) 
Difficulty injecting 
   Discriminated monthly 1.5 (1.0-2.3) 2.8 (1.3-6.0) 1.1 (0.7-1.8) 
Discriminated  weekly or 
more 2.0 (1.4-2.8) 2.7 (1.4-5.4) 1.9 (1.2-2.9) 
Self-reported mental health problems 
  Discriminated monthly 1.6 (1.1-2.3) 1.2 (0.5-2.5) 1.4 (0.9-2.1) 
Discriminated  weekly or 
more 1.8 (1.2-2.6) 2.4 (1.2-4.9) 1.8 (1.1-2.8) 
Note: reference category is no discrimination/not in the previous 12 months 
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Table 4. Interaction model  of health indicators in relation to timeframe of discrimination, by Aboriginal/Torres Strait Island origin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: reference category is no discrimination/not in the previous 12 months 
 
 Any origin ATSIa Non-ATSI 
Overdose 
   Discriminated monthly 1.2 (0.8-1.8) 0.7 (0.2-2.1) 1.2 (0.8-1.8) 
Discriminated  weekly or more 1.6 (1.1-2.3) 1.2 (0.5-2.1) 1.7 (1.1-2.6) 
Self-reported mental health problems 
  Discriminated monthly 1.6 (1.1-2.3) 3.1 (1.0-9.7) 1.2 (0.8-1.8) 
Discriminated  weekly or more 
1.8 (1.2-2.6) 
4.9 (1.7-
14.1) 1.7 (1.1-2.6) 
Personal Wellbeing Index poorer than Australian mean 
 Discriminated monthly 1.7 (1.1-2.8) 1.4 (0.4-4.2) 1.8 (1.0-3.1) 
Discriminated  weekly or more 
2.9 (1.7-4.2) 
9.5 (2.6-
34.5) 2.2 (1.2-3.8) 
a Aboriginal/Torres Strait Islander  
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